A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis
Dávid Tornai(Beth Israel Deaconess Medical Center), Gyöngyi Szabó(Beth Israel Deaconess Medical Center), Mack C. Mitchell(Southwestern Medical Center), Svetlana Radaeva(National Institute on Alcohol Abuse and Alcoholism), Craig J. McClain(University of Louisville), Aimee Kroll‐Desrosiers(University of Massachusetts Chan Medical School), Jung-Ae Lee(University of Massachusetts Chan Medical School), Arthur J. McCullough(Cleveland Clinic), Bruce Barton(University of Massachusetts Chan Medical School), Srinivasan Dasarathy(Cleveland Clinic)
Cited by 6
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k
Endpoints and clinical trial design for nonalcoholic steatohepatitis
|Hepatology|2011|757